Direxion Daily TSLA Bull 1.5X Shares

Mast Therapeutics, Inc.

GraniteShares 1.5x Long NVDA Daily ETF

GraniteShares 1.5x Long META Daily ETF

GraniteShares 1.5x Long Coinbase Daily ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

AXS 2X Innovation ETF

Volatility Shares Trust 2x Ether ETF

Direxion Daily Technology Bull 3X ETF

VS TR 2x Long VIX Futures ETF

ProShares Ultra VIX Short-Term Futures

MicroSectors Gold Miners 3X Leveraged ETN

Bank Of Montreal

iShares Nasdaq Biotechnology

Direxion Technology Bear 3X Shares

iPath S&P 500 VIX ST Futures ETN

ProShares UltraPro Short QQQ

Direxion Daily Gold Miners Bull 3X ETF

BigBear.ai Inc. Common Stock

Spire Global Inc. Class A Common Stock

Pony AI Inc. American Depositary Shares

Charter Communications Inc. Class A Common Stock New

Rezolve AI Limited Ordinary Shares

Tesla Inc. Common Stock

Comfort Systems USA Inc. Common Stock

PENN Entertainment Inc. Common Stock

SolarEdge Technologies Inc. Common Stock

RE/MAX Holdings Inc. Class A Common Stock

Adecoagro S.A. Common Shares

Carter's Inc. Common Stock

T-Mobile US Inc. Common Stock

Old Dominion Freight Line Inc. Common Stock

Intel Corporation Common Stock

Annexon Inc. Common Stock

Eastern Bankshares Inc. Common Stock

Skechers U.S.A. Inc. Common Stock

Apollo Global Management Inc. (New) Common Stock

Click here to get full coverage on Nona Biosciences' Partner Pfizer Presents Preclinical Data on TOP1i-Based ADC Targeting MSLN at AACR Annual Meeting 2025 - PR Newswire

Nona Biosciences' Partner Pfizer Presents Preclinical Data on TOP1i-Based ADC Targeting MSLN at AACR Annual Meeting 2025  PR Newswire

Nona Biosciences' Partner Pfizer Presents Preclinical Data on TOP1i-Based ADC Targeting MSLN at AACR Annual Meeting 2025 - PR Newswire

Click here to get full coverage on Synthetic Design Lab Emerges with $20M to Advance Next-Generation ADCs - Business Wire

Synthetic Design Lab Emerges with $20M to Advance Next-Generation ADCs  Business Wire

Synthetic Design Lab Emerges with $20M to Advance Next-Generation ADCs - Business Wire

Click here to get full coverage on FDA’s New ADC Approval Raises Questions About Sequencing in Breast Cancer - Oncology News Central

FDA’s New ADC Approval Raises Questions About Sequencing in Breast Cancer  Oncology News Central

FDA’s New ADC Approval Raises Questions About Sequencing in Breast Cancer - Oncology News Central

Click here to get full coverage on ADC startup sets sights on 10-fold improvement in targeted payload delivery - FirstWord Pharma

ADC startup sets sights on 10-fold improvement in targeted payload delivery  FirstWord Pharma

ADC startup sets sights on 10-fold improvement in targeted payload delivery - FirstWord Pharma

Click here to get full coverage on Historic Lawsuit Filed by ADC and Partners Challenging Attack on Free Speech; National Injunction Demanded - American-Arab Anti-Discrimination Committee - ADC

Historic Lawsuit Filed by ADC and Partners Challenging Attack on Free Speech; National Injunction Demanded  American-Arab Anti-Discrimination Committee - ADC

Historic Lawsuit Filed by ADC and Partners Challenging Attack on Free Speech; National Injunction Demanded - American-Arab Anti-Discrimination Committee - ADC

Click here to get full coverage on Swiss ADC Biotech Takes SPAC Track to NASDAQ - BioSpace

Swiss ADC Biotech Takes SPAC Track to NASDAQ  BioSpace

Swiss ADC Biotech Takes SPAC Track to NASDAQ - BioSpace

Click here to get full coverage on Akoya Biosciences Expands Biopharma Service Portfolio with - GlobeNewswire

Akoya Biosciences Expands Biopharma Service Portfolio with  GlobeNewswire

Akoya Biosciences Expands Biopharma Service Portfolio with - GlobeNewswire

Click here to get full coverage on Agree Realty Raises $392M in Oversubscribed Stock Offering with Flexible Settlement Terms - Stock Titan

Agree Realty Raises $392M in Oversubscribed Stock Offering with Flexible Settlement Terms  Stock Titan

Agree Realty Raises $392M in Oversubscribed Stock Offering with Flexible Settlement Terms - Stock Titan

Click here to get full coverage on Agree Realty Corp (ADC) Q1 2025 Earnings Call Highlights: Strong Investment Growth and Solid ... - Yahoo Finance

Agree Realty Corp (ADC) Q1 2025 Earnings Call Highlights: Strong Investment Growth and Solid ...  Yahoo Finance

Agree Realty Corp (ADC) Q1 2025 Earnings Call Highlights: Strong Investment Growth and Solid ... - Yahoo Finance

Click here to get full coverage on Decades after bomb attack, Arab American advocacy group opens new Anaheim office - Los Angeles Times

Decades after bomb attack, Arab American advocacy group opens new Anaheim office  Los Angeles Times

Decades after bomb attack, Arab American advocacy group opens new Anaheim office - Los Angeles Times

Click here to get full coverage on Genentech vet launches ADC startup with $20M - Endpoints News

Genentech vet launches ADC startup with $20M  Endpoints News

Genentech vet launches ADC startup with $20M - Endpoints News

Click here to get full coverage on Next-generation ADCs are poised to transform the cancer treatment paradigm - Science | AAAS

Next-generation ADCs are poised to transform the cancer treatment paradigm  Science | AAAS

Next-generation ADCs are poised to transform the cancer treatment paradigm - Science | AAAS

Click here to get full coverage on Precision Biologics to Present Recent Data on a New Antibody-Drug Conjugate (ADC) Utilizing the Monoclonal Antibody (mAb) PB-223, at AACR Annual Meeting 2025 - PR Newswire

Precision Biologics to Present Recent Data on a New Antibody-Drug Conjugate (ADC) Utilizing the Monoclonal Antibody (mAb) PB-223, at AACR Annual Meeting 2025  PR Newswire

Precision Biologics to Present Recent Data on a New Antibody-Drug Conjugate (ADC) Utilizing the Monoclonal Antibody (mAb) PB-223, at AACR Annual Meeting 2025 - PR Newswire

Click here to get full coverage on NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025 - BioSpace

NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025  BioSpace

NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025 - BioSpace

Click here to get full coverage on Agree Realty (ADC) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

Agree Realty (ADC) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates  Yahoo Finance

Agree Realty (ADC) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

Click here to get full coverage on Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago - Business Wire

Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago  Business Wire

Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago - Business Wire

Click here to get full coverage on New Cancer Drugs: Innovent Unveils 6 Novel Antibody Treatments at AACR | IVBIY Stock News - Stock Titan

New Cancer Drugs: Innovent Unveils 6 Novel Antibody Treatments at AACR | IVBIY Stock News  Stock Titan

New Cancer Drugs: Innovent Unveils 6 Novel Antibody Treatments at AACR | IVBIY Stock News - Stock Titan

Click here to get full coverage on Lotte Bio launches ADC services; Ypsomed to focus on self-injection business - Endpoints News

Lotte Bio launches ADC services; Ypsomed to focus on self-injection business  Endpoints News

Lotte Bio launches ADC services; Ypsomed to focus on self-injection business - Endpoints News

Click here to get full coverage on Revolutionary Breast Cancer Detection: Akoya's New ADC Assay Targets HER2-Low and TROP2 Biomarkers - Stock Titan

Revolutionary Breast Cancer Detection: Akoya's New ADC Assay Targets HER2-Low and TROP2 Biomarkers  Stock Titan

Revolutionary Breast Cancer Detection: Akoya's New ADC Assay Targets HER2-Low and TROP2 Biomarkers - Stock Titan

Click here to get full coverage on Agree Realty Unveils Strategic 4.5M Share Offering: Forward Sale Structure Targets Property Expansion - Stock Titan

Agree Realty Unveils Strategic 4.5M Share Offering: Forward Sale Structure Targets Property Expansion  Stock Titan

Agree Realty Unveils Strategic 4.5M Share Offering: Forward Sale Structure Targets Property Expansion - Stock Titan

Click here to get full coverage on Management of ADC-Related AEs - Targeted Oncology

Management of ADC-Related AEs  Targeted Oncology

Management of ADC-Related AEs - Targeted Oncology

Click here to get full coverage on CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025 - BioSpace

CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025  BioSpace

CatalYm to Present New Data Demonstrating GDF-15 Blockade Enhances Efficacy of Antibody-Drug Conjugates at AACR 2025 - BioSpace

Click here to get full coverage on One of the largest preclinical ADC deals: Taiho Pharma’s US$1.14bn acquisition of Araris Biotech - Investors in Healthcare

One of the largest preclinical ADC deals: Taiho Pharma’s US$1.14bn acquisition of Araris Biotech  Investors in Healthcare

One of the largest preclinical ADC deals: Taiho Pharma’s US$1.14bn acquisition of Araris Biotech - Investors in Healthcare

Click here to get full coverage on 2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs - The Manila Times

2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs  The Manila Times

2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs - The Manila Times

Click here to get full coverage on ADC Rejects President Trump’s “Travel Ban” Executive Order - American-Arab Anti-Discrimination Committee - ADC

ADC Rejects President Trump’s “Travel Ban” Executive Order  American-Arab Anti-Discrimination Committee - ADC

ADC Rejects President Trump’s “Travel Ban” Executive Order - American-Arab Anti-Discrimination Committee - ADC

Click here to get full coverage on Akoya Unveils ADC Breast Cancer Assay, Validates IO60 Spatial Panel At AACR 2025 - Nasdaq

Akoya Unveils ADC Breast Cancer Assay, Validates IO60 Spatial Panel At AACR 2025  Nasdaq

Akoya Unveils ADC Breast Cancer Assay, Validates IO60 Spatial Panel At AACR 2025 - Nasdaq

Click here to get full coverage on ADC Statement on Dr. Lara Sheehi Cleared of Baseless Allegations Fabricated by StandWithUs - American-Arab Anti-Discrimination Committee - ADC

ADC Statement on Dr. Lara Sheehi Cleared of Baseless Allegations Fabricated by StandWithUs  American-Arab Anti-Discrimination Committee - ADC

ADC Statement on Dr. Lara Sheehi Cleared of Baseless Allegations Fabricated by StandWithUs - American-Arab Anti-Discrimination Committee - ADC

Click here to get full coverage on Urgent Community Advisory: Impending Arab, Muslim Ban - American-Arab Anti-Discrimination Committee - ADC

Urgent Community Advisory: Impending Arab, Muslim Ban  American-Arab Anti-Discrimination Committee - ADC

Urgent Community Advisory: Impending Arab, Muslim Ban - American-Arab Anti-Discrimination Committee - ADC

Click here to get full coverage on ADC Development in Ovarian Cancer: What's Next for FRa and Beyond? - OncLive

ADC Development in Ovarian Cancer: What's Next for FRa and Beyond?  OncLive

ADC Development in Ovarian Cancer: What's Next for FRa and Beyond? - OncLive

Click here to get full coverage on Agree Realty (ADC) Tops Q1 FFO and Revenue Estimates - Yahoo Finance

Agree Realty (ADC) Tops Q1 FFO and Revenue Estimates  Yahoo Finance

Agree Realty (ADC) Tops Q1 FFO and Revenue Estimates - Yahoo Finance

Click here to get full coverage on ADC Statement on Louisiana Immigration Judge’s Ruling in Mahmoud Khalil Case - American-Arab Anti-Discrimination Committee - ADC

ADC Statement on Louisiana Immigration Judge’s Ruling in Mahmoud Khalil Case  American-Arab Anti-Discrimination Committee - ADC

ADC Statement on Louisiana Immigration Judge’s Ruling in Mahmoud Khalil Case - American-Arab Anti-Discrimination Committee - ADC

Click here to get full coverage on From ADCs to radiopharma: How AstraZeneca is trying to 'redefine oncology care' - Fierce Biotech

From ADCs to radiopharma: How AstraZeneca is trying to 'redefine oncology care'  Fierce Biotech

From ADCs to radiopharma: How AstraZeneca is trying to 'redefine oncology care' - Fierce Biotech

Click here to get full coverage on ADC Posts Strong Data in Heavily Pretreated, Advanced NSCLC Trial - Oncology News Central

ADC Posts Strong Data in Heavily Pretreated, Advanced NSCLC Trial  Oncology News Central

ADC Posts Strong Data in Heavily Pretreated, Advanced NSCLC Trial - Oncology News Central

Click here to get full coverage on ADC Announces Its 24/7 Legal Hotline - American-Arab Anti-Discrimination Committee - ADC

ADC Announces Its 24/7 Legal Hotline  American-Arab Anti-Discrimination Committee - ADC

ADC Announces Its 24/7 Legal Hotline - American-Arab Anti-Discrimination Committee - ADC

Click here to get full coverage on Metastatic Castration-Resistant Prostate Cancer: Immune-Modulating ADC Targeting CD46 - The ASCO Post

Metastatic Castration-Resistant Prostate Cancer: Immune-Modulating ADC Targeting CD46  The ASCO Post

Metastatic Castration-Resistant Prostate Cancer: Immune-Modulating ADC Targeting CD46 - The ASCO Post

Click here to get full coverage on ADC Emergency Know Your Rights Town Hall - American-Arab Anti-Discrimination Committee - ADC

ADC Emergency Know Your Rights Town Hall  American-Arab Anti-Discrimination Committee - ADC

ADC Emergency Know Your Rights Town Hall - American-Arab Anti-Discrimination Committee - ADC

Click here to get full coverage on ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update - PR Newswire

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update  PR Newswire

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update - PR Newswire

Click here to get full coverage on Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech - GlobeNewswire

Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech  GlobeNewswire

Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech - GlobeNewswire

Click here to get full coverage on Refining and targeting exatecan with ADC technology - Drug Target Review

Refining and targeting exatecan with ADC technology  Drug Target Review

Refining and targeting exatecan with ADC technology - Drug Target Review

Click here to get full coverage on BMS expands SystImmune's ADC programme with first-line TNBC trial - FirstWord Pharma

BMS expands SystImmune's ADC programme with first-line TNBC trial  FirstWord Pharma

BMS expands SystImmune's ADC programme with first-line TNBC trial - FirstWord Pharma

Click here to get full coverage on ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PR Newswire

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan  PR Newswire

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PR Newswire

Click here to get full coverage on Breaking: ADC Condemns New AI-Driven Attack on International Students - American-Arab Anti-Discrimination Committee - ADC

Breaking: ADC Condemns New AI-Driven Attack on International Students  American-Arab Anti-Discrimination Committee - ADC

Breaking: ADC Condemns New AI-Driven Attack on International Students - American-Arab Anti-Discrimination Committee - ADC

Click here to get full coverage on Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics - Fierce Biotech

Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics  Fierce Biotech

Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics - Fierce Biotech

Click here to get full coverage on Breakthrough Cancer Drug EO-1022 Outperforms Existing HER3 Therapies in Stability and Anti-Tumor Activity - Stock Titan

Breakthrough Cancer Drug EO-1022 Outperforms Existing HER3 Therapies in Stability and Anti-Tumor Activity  Stock Titan

Breakthrough Cancer Drug EO-1022 Outperforms Existing HER3 Therapies in Stability and Anti-Tumor Activity - Stock Titan

Click here to get full coverage on ADC Denounces Blanket Visa Revocation for South Sudanese Nationals as Unjust and Dangerous Precedent - American-Arab Anti-Discrimination Committee - ADC

ADC Denounces Blanket Visa Revocation for South Sudanese Nationals as Unjust and Dangerous Precedent  American-Arab Anti-Discrimination Committee - ADC

ADC Denounces Blanket Visa Revocation for South Sudanese Nationals as Unjust and Dangerous Precedent - American-Arab Anti-Discrimination Committee - ADC

Click here to get full coverage on Emerging ADC Clinical Trial Evidence in Breast Cancer Treatment - Pharmacy Times

Emerging ADC Clinical Trial Evidence in Breast Cancer Treatment  Pharmacy Times

Emerging ADC Clinical Trial Evidence in Breast Cancer Treatment - Pharmacy Times

Click here to get full coverage on FDA Grants B7-H3–Targeted ADC Breakthrough Status in Osteosarcoma - Targeted Oncology

FDA Grants B7-H3–Targeted ADC Breakthrough Status in Osteosarcoma  Targeted Oncology

FDA Grants B7-H3–Targeted ADC Breakthrough Status in Osteosarcoma - Targeted Oncology

Click here to get full coverage on Discovery of a Novel ADC for Multifunctional Theranostics: From Vascular Normalization to Synergistic Therapy - ACS Publications

Discovery of a Novel ADC for Multifunctional Theranostics: From Vascular Normalization to Synergistic Therapy  ACS Publications

Discovery of a Novel ADC for Multifunctional Theranostics: From Vascular Normalization to Synergistic Therapy - ACS Publications

Click here to get full coverage on ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - PR Newswire

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference  PR Newswire

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - PR Newswire

Click here to get full coverage on DCS, G-9 participates in 2025 ADC - army.mil

DCS, G-9 participates in 2025 ADC  army.mil

DCS, G-9 participates in 2025 ADC - army.mil

Click here to get full coverage on IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - PR Newswire

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors  PR Newswire

IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - PR Newswire

Click here to get full coverage on Expanding new trends and technologies in ADC therapeutics - News-Medical

Expanding new trends and technologies in ADC therapeutics  News-Medical

Expanding new trends and technologies in ADC therapeutics - News-Medical

Click here to get full coverage on Radiance rolls into ROR1 race, paying $15M for ADC rival to Merck’s frontrunner - Fierce Biotech

Radiance rolls into ROR1 race, paying $15M for ADC rival to Merck’s frontrunner  Fierce Biotech

Radiance rolls into ROR1 race, paying $15M for ADC rival to Merck’s frontrunner - Fierce Biotech

Click here to get full coverage on Pfizer axes B7-H4 ADC, triggering $1B impairment charge as blockbuster vision evaporates - Fierce Biotech

Pfizer axes B7-H4 ADC, triggering $1B impairment charge as blockbuster vision evaporates  Fierce Biotech

Pfizer axes B7-H4 ADC, triggering $1B impairment charge as blockbuster vision evaporates - Fierce Biotech

Click here to get full coverage on Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones - PR Newswire

Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones  PR Newswire

Agree Realty Corporation (ADC)

Price Chart

Key Statistics

Technicals

About ADC

Latest News

Nona Biosciences' Partner Pfizer Presents Preclinical Data on TOP1i-Based ADC Targeting MSLN at AACR Annual Meeting 2025 - PR Newswire

Synthetic Design Lab Emerges with $20M to Advance Next-Generation ADCs - Business Wire

FDA’s New ADC Approval Raises Questions About Sequencing in Breast Cancer - Oncology News Central

Advanced Charts

Top Gainers

Top Losers